Botanix Pharmaceuticals (ASX: BOT) hosted an investor update webinar following the announcement of its acquisition of Sofpironium Bromide, the first and only novel treatment for primary axillary hyperhidrosis.

Present on the call was President and Executive Chairman, Vince Ippolito; Executive Director, Matt Callahan; Chief Medical Adviser, Dr Patricia Walker; and Chief Commercial Officer, Howie McKibbon.

свернуть